Why the study?
Does Ginsenoside Rg3 inhibit hypoxia-induced VEGF expression in human cancer cells?
Population
Human esophageal carcinoma cell line Eca-109 and 786-0 cells
Comparison
Ginsenoside Rg3 vs Untreated cells under normoxic and hypoxic…
Design
Preclinical
Key result
Ginsenoside Rg3 inhibited hypoxia-induced VEGF expression, cell proliferation, and multiple signaling pathways (HIF-1α, COX-2, NF-κB, STAT3, ERK1/2, JNK) in human cancer cells.
Authors
Loading...
Hypothesis-generating for anti-angiogenic effects in cancer; leaves open clinical translation pending human trials.
Does Ginsenoside Rg3 inhibit hypoxia-induced VEGF expression in human cancer cells?
Ginsenoside Rg3 down-regulates VEGF expression in cancer cells by targeting multiple hypoxia-induced signaling pathways, providing a mechanistic basis for its anti-angiogenic and anti-tumor efficacy.
Chen et al. (2010) studied Human esophageal carcinoma and renal cell carcinoma (Eca-109 and 786-0 cells). Ginsenoside Rg3 was evaluated on VEGF expression, cell proliferation, and signaling pathway activation. Ginsenoside Rg3 inhibited hypoxia-induced VEGF expression, cell proliferation, and multiple signaling pathways (HIF-1α, COX-2, NF-κB, STAT3, ERK1/2, JNK) in human cancer cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: